Sepsis is a major growing global burden and a major challenge to intensive care clinicians,
researchers, guideline committee members and policy makers, because of its high and …

A systematic review of the literature was conducted to determine if the administration of
methylene blue in humans improves hemodynamic status and/or outcome in patients with …

Purpose Methylene blue (MB) has been tested as a rescue therapy for patients with
refractory septic shock. However, there is a lack of evidence on MB as an adjuvant therapy …

Refractory hypotension with end-organ hypoperfusion and failure is an ominous feature of
shock. Distributive shock is caused by severe infections (septic shock) or severe systemic …

Sepsis is one of the most frequent causes of death among patients in intensive care units.
Many therapeutic strategies have been assessed without the desired success rates. A key …

Methylene blue (MB) has received much attention in the perioperative and critical care
literature because of its ability to antagonize the profound vasodilation seen in distributive …

Methylene blue is used primarily in the treatment of patients with methemoglobinemia. Most
recently, methylene blue has been used as a treatment for refractory distributive shock from …

Background The role of methylene blue (MB) in patients with vasodilatory shock is unclear.
The purpose of this systematic review and meta-analysis was to evaluate the efficacy and …

Background Historically, methylene blue (MB) has been used for multiple purposes,
including as an antidote for toxin-induced and hereditary methemoglobinemia, ifosfamide …

Purpose Methylene blue (MB) has recently been reevaluated for malaria treatment. With the
aim of excluding treatment failures due to low bioavailability, we have investigated the …